Precision Medicine

Breathalyser Test Can Predict Which Patients Will Respond to Lung Cancer Immunotherapy

A newly developed ‘electronic nose’ can measure chemicals in the breath of small cancer lung patients to determine if they will respond to immunotherapy treatment. Immunotherapy is Changing Cancer Care Immunotherapy treatments harness the body’s immune system to fight the cancer cells, which is transforming the treatment of advanced stage cancers. However, only a small […]

Colour Changing Tattoos Can Sense Biomarkers

Scientists have developed tattoos that change colour depending on the interstitial fluid concentration of key biomarkers. The development is a step towards developing quicker diagnostics. The biomarkers studied were pH, glucose and albumin. Variation of blood pH can be indictive of a range of health conditions and glucose sensing is extremely useful for monitoring diabetes. […]

Genomic Barcode Identifies Immune Cells that Can Tackle Cancer

Researchers have developed a new technique to pinpoint immune cells in cancer patients that are reactive against their disease. This research could lead to more targeted immune-based therapies for cancer patients. Immunotherapy is a relatively new field of cancer treatment which works by promoting the patient’s immune system to fight against the cancer. Although immune […]

Largest DNA-Mapping Study of a Single US Population Begins

Intermountain Healthcare and deCODE Genetics, a subsidiary of Amgen based in Iceland, have announced a major joint collaboration and study of 500,000 genomes centred around discovering new connections between genetics and human diseases. The study represents the largest US DNA-mapping attempt from a single population.

BIO 2019 – An Interview with Irene Rombel, Senior Director and Head of Strategic Analysis at Janssen

With the recent conclusion of the Biotechnology Innovation Organization’s BIO 2019 event, we thought we’d talk to some of the fascinating individuals who were present to showcase their innovative ideas or technologies. Irene Rombel, Senior Director, Head of Strategic Analysis – External Innovation, Discovery, Product Development & Supply, at Janssen Research & Development, spoke at BIO 2019 about gene therapy and the next generation of biotherapeutics. We spoke to her about her thoughts on the gene therapy field, and the future for companies in that space.

Gold Nanoparticles Improves CRISPR Cell Delivery

Researchers at the Fred Hutchinson Cancer Research Center have proposed gold nanoparticles as a new way to deliver CRISPR Cas-12a to cells. These nanoparticles can be filled with the necessary CRISPR components to edit genes cleanly, with between 10% and 20% of targeted cells successfully edited during lab studies. No toxic side effects were found from the process.

Protein and Receptor Combination Slows Metastasis in Mouse Models

Swiss scientists have found a potential new way to block metastasis, with promising results demonstrated in mice. The researchers have found a “barrier”, built by the Activin B protein and a receptor called ALK7, the combo of which prevents tumours from spreading through the body.

The One-Stop Guide to Genomic Data, Courtesy of Front Line Genomics

Front Line Genomics’ “Biodata Analysis and Management – Genome Analytics, Interoperability, and Data Life Cycle” report isn’t just an update of our old Genomic Data 101 guides: packed with new information on AI and machine learning,. data discoverability and data interoperability, it is much much more.

More Than 13,000 Genetic Edits Made to Single Cell

Harvard College researchers have announced that more than 13,000 genetic alterations have been made to a single cell using CRISPR technology. This work is designed to edit genomes at a much larger scale than currently possible.

Second Set of “Semi-Identical Twins” Identified

Twins born in Australia have become the second-ever-identified pair of “semi-identical” twins, and the first to be detected before they were born. Such cases come about when twins receive 100% identical genes from their mother, but not from their father.

“Trojan Horse” Antibody to Treat Cancers Reaches New Test Stage

Toxic antibody tisutumab vedotin (TV) has shown promise as a treatment for a number of types of advanced cancer. This “trojan horse” approach has now reached the stage of being tested on a wider variety of patients. Institute of Cancer Research and Royal Marsden NHS Foundation Trust researchers tested the drug on 147 patients to evaluate potential benefits and side effects.